{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:11:59Z","timestamp":1793787119876,"version":"4.6.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.breast.2025.104573","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:10:23Z","timestamp":1757542223000},"page":"104573","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Capacity and cost benefits of subcutaneous versus intravenous pertuzumab\/trastuzumab: The EASE-SC study"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1497-3033","authenticated-orcid":false,"given":"Michiel","family":"Zietse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacky","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther R.","family":"van Staveren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leontine E.A.M.M.","family":"Spierings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit C.P.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5667-5697","authenticated-orcid":false,"given":"Ron H.J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roelof W.F.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0312-5891","authenticated-orcid":false,"given":"Frederick W.","family":"Thielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10087","key":"10.1016\/j.breast.2025.104573_bib1","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.breast.2025.104573_bib2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.breast.2025.104573_bib3","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","volume":"17","author":"Gianni","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.breast.2025.104573_bib4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-Positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.breast.2025.104573_bib8","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/S1470-2045(20)30605-7","article-title":"Oncology nursing workforce: challenges, solutions, and future strategies","volume":"21","author":"Challinor","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.breast.2025.104573_bib9","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1470-2045(23)00267-X","article-title":"Concern over cancer treatment delays caused by staffing shortages","volume":"24","author":"Gourd","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.breast.2025.104573_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1470-2045(20)30536-2","article-title":"Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study","volume":"22","author":"Tan","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.breast.2025.104573_bib12","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s12325-021-01996-0","article-title":"White paper on the value of time savings for patients and healthcare providers of breast cancer therapy: the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection as an example","volume":"39","author":"Jackisch","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.breast.2025.104573_bib13","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.breast.2016.07.008","article-title":"Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer - an observational study prospectively recording resource utilization in a Swedish healthcare setting","volume":"29","author":"Olofsson","year":"2016","journal-title":"Breast"},{"key":"10.1016\/j.breast.2025.104573_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.breast.2020.05.001","article-title":"Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab","volume":"52","author":"Franken","year":"2020","journal-title":"Breast"},{"issue":"8","key":"10.1016\/j.breast.2025.104573_bib15","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/CAD.0000000000000648","article-title":"Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands","volume":"29","author":"Franken","year":"2018","journal-title":"Anti Cancer Drugs"},{"issue":"1","key":"10.1016\/j.breast.2025.104573_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s41669-022-00361-3","article-title":"A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting","volume":"7","author":"McCloskey","year":"2023","journal-title":"Pharmacoecon Open"},{"issue":"6","key":"10.1016\/j.breast.2025.104573_bib17","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jval.2015.05.009","article-title":"The iMTA productivity cost questionnaire: a standardized instrument for measuring and valuing health-related productivity losses","volume":"18","author":"Bouwmans","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.breast.2025.104573_bib18","series-title":"Costing manual for economic evaluations in healthcare: methodology and reference prices, p59-60. National Health Care Institute (ZIN) Version2024. [in Dutch: Kostenhandleiding voor economische evaluaties in de gezondheidszorg","author":"Hakkaart-van Roijen","year":"2024"},{"key":"10.1016\/j.breast.2025.104573_bib19","article-title":"Dutch guideline for conducting economic evaluations in healthcare [in Dutch: Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidzorg]","year":"2024","journal-title":"National Health Care Institute (ZIN)"},{"issue":"1","key":"10.1016\/j.breast.2025.104573_bib22","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1186\/s12913-024-11719-0","article-title":"The administration of immune checkpoint inhibitors via an elastomeric pump versus conventional intravenous infusion: an economic perspective","volume":"24","author":"Zietse","year":"2024","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.breast.2025.104573_bib23","unstructured":"Collective labor agreement academic medical centers 2022-2023. Dutch Federation of Academic Medical Centers [NFU)]."},{"key":"10.1016\/j.breast.2025.104573_bib24","unstructured":"Collective Labour Agreement Hospitals 2023-2025. Dutch Association of Hospitals (NVZ)."},{"issue":"2","key":"10.1016\/j.breast.2025.104573_bib25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00019053-200523020-00002","article-title":"The friction-cost method","volume":"23","author":"Brouwer","year":"2005","journal-title":"Pharmacoecnomics"},{"key":"10.1016\/j.breast.2025.104573_bib26","series-title":"Methods for the economic evaluation of health care programmes","first-page":"219","article-title":"Chapter 7: cost analysis","author":"Drummond","year":"2015"},{"key":"10.1016\/j.breast.2025.104573_bib28","doi-asserted-by":"crossref","DOI":"10.1007\/s10198-023-01648-w","article-title":"The impact of an 'evergreening' strategy nearing patent expiration on the uptake of biosimilars and public healthcare costs: a case study on the introduction of a second administration form of trastuzumab in the Netherlands","author":"Kirshner","year":"2024","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.breast.2025.104573_bib29","unstructured":"Munzone E, Fabi A, Buono G, Caputo R, Montagna E, Negri M, et al. The PHASTER study: economic and organizational impact of subcutaneous (SC) pertuzumab and trastuzumab fixed-dose combination (PH FDC SC) for treatment of HER2+ breast cancer patients."},{"key":"10.1016\/j.breast.2025.104573_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(24)00516-3","article-title":"Rising costs of cancer medicines","author":"Devi","year":"2024","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.breast.2025.104573_bib31","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.19.01963","article-title":"Trends in the cost of cancer care: beyond drugs","volume":"38","author":"Laviana","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2025.104573_bib32","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40258-024-00937-6","article-title":"Cost-effective and sustainable drug use in hospitals: a systematic and practice-based approach","volume":"23","author":"Zietse","year":"2025","journal-title":"Appl Health Econ Health Policy"},{"issue":"6","key":"10.1016\/j.breast.2025.104573_bib33","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.clinthera.2017.05.342","article-title":"Microcosting study of Rituximab subcutaneous injection versus intravenous infusion","volume":"39","author":"Mihajlovic","year":"2017","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.breast.2025.104573_bib34","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/cam4.573","article-title":"A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer","volume":"5","author":"De Cock","year":"2016","journal-title":"Cancer Med"},{"issue":"12","key":"10.1016\/j.breast.2025.104573_bib35","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1007\/s12094-017-1684-4","article-title":"Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain","volume":"19","author":"Lopez-Vivanco","year":"2017","journal-title":"Clin Transl Oncol"},{"issue":"7 Suppl 1","key":"10.1016\/j.breast.2025.104573_bib36","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1097\/MLR.0b013e31819bc064","article-title":"Microcosting quantity data collection methods","volume":"47","author":"Frick","year":"2009","journal-title":"Med Care"},{"issue":"1","key":"10.1016\/j.breast.2025.104573_bib37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10198-008-0101-x","article-title":"Comparing methodologies for the cost estimation of hospital services","volume":"10","author":"Tan","year":"2009","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.breast.2025.104573_bib39","author":"van Volksgezondheid"},{"issue":"5","key":"10.1016\/j.breast.2025.104573_bib42","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities","volume":"32","author":"Bittner","year":"2018","journal-title":"BioDrugs"},{"issue":"3","key":"10.1016\/j.breast.2025.104573_bib43","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/cpt.3150","article-title":"Subcutaneous administration of monoclonal antibodies: pharmacology, delivery, immunogenicity, and learnings from applications to clinical development","volume":"115","author":"Davis","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.breast.2025.104573_bib44","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13223-022-00735-6","article-title":"Economic impact of self-administered subcutaneous versus clinic-administered intravenous immunoglobulin G therapy in Alberta, Canada: a population-based cohort study","volume":"18","author":"Ritchie","year":"2022","journal-title":"Allergy Asthma Clin Immunol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625005909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625005909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:14:41Z","timestamp":1764029681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977625005909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":34,"alternative-id":["S0960977625005909"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2025.104573","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Capacity and cost benefits of subcutaneous versus intravenous pertuzumab\/trastuzumab: The EASE-SC study","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2025.104573","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104573"}}